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ABSTRACT
Since March 2020, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
infection has been around in Indonesia with a case fatality rate was 4.7% on August, 1th 2020. So
far, the Real-Time Polymerase Chain Reaction (RT-PCR) method is the gold standard for the
SARS-CoV-2 infection diagnosis. This method, however, has some limitations where it has a long
turnaround time, complicated operations, and high prices. Hence, the rapid test kits are now
readily available to identify the SARS-CoV-2 patients. The purpose of this study is to measure the
diagnostic performance, including sensitivity, specificity, positive and negative predictive value,
likelihood ratio or LR of antibody rapid test if compared with RT-PCR for the SARS-CoV-2
suspected patients in Bethesda Hospital Yogyakarta. This research was analytical observational
research with a cross-sectional design approach, in which data were collected retrospectively. The
instruments used in this study included e-medical record (ERM), Laboratory Information
System (LIS) data from patients with suspected SARS-CoV-2 infection in Bethesda Hospital
Yogyakarta. We collected demographic data of patients, RT-PCR results, antibody rapid test
results using Standard Q COVID-19 IgM/IgG Combo. The data were obtained from 50 patients.
The results showed that the Rapid test kit has a 100% sensitivity value, 74.4% specificity value,
38.9% positive and 100% negative predictive value, 3906 positive likelihood ratio compared with
the RT-PCR results.
Keywords: Rapid antibody test; RT-PCR; SARS-CoV-2
INTRODUCTION
Severe Acute Respiratory Syndrome
Coronavirus-2 (SARS-CoV-2) infection is an
ongoing respiratory disease outbreak caused
by Coronavirus that firstly emerged in
Wuhan City, China, in December 2019
(WHO, 2020). Since the first case of the
disease was reported at the end of 2019 in
Wuhan, it has spread widely to entire China
and multiple countries (WHO, 2020).
According to the statistic information
from the Indonesian Health Ministry on
August, 1st 2020, there were 109,936 cases
confirmed for SARS-CoV-2, which divided
into 36,824 active cases, 67,919 cured cases,
and 5193 death cases. There are 1,517,381
specimen tested coming from 875,894
Indonesian citizens. In Daerah Istimewa
Yogyakarta, there were 10,126 suspected
cases, 741 confirmed cases, 410 cured cases,
and 21 death cases until August 1, 2020
(PEMDA DIY, 2020).
Indonesia has recorded an 8.4% fatality
rate in April 2020 and decreased to 4.72% in
August 2020. Meanwhile, in August, the
positivity rate in Indonesia was still 12.6%,
which was considered very high and
exceeded the limit set by WHO (2020) that is
less than 5%. The increasing SARS-CoV-2
infection cases in Indonesia have caused a
few complex problems, including the
availability of facilities to screen and
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confirm a COVID-19 diagnosis. Currently,
the Real-Time Polymerase Chain Reaction
method (RT-PCR) is the gold standard of
SARS-COV-2 testing (Kahfarhood et al.,
2020).
However, there are some limitations to
the RT-PCR method. It will need a certified
laboratory with a specific classification for
safety. It also takes a long time from sample
preparation until the test result. Also, it is
costly and complicated in operations (Li et
al., 2020). Even though RT-PCR is the gold-
standard method in diagnosing the SARS-
CoV-2 infection, the sensitivity of this
method is only 50% to 70% due to the small
number of virus particles in some infected
patients. The best specimen for virus
detection is Broncho Alveolar Lavage (BAL).
However, until now, the test majorly takes
the samples from the nasopharyngeal or
oropharyngeal swabs. The false-negative
could happen if the sampling quality or the
sample management is poor. It could also
give false-negative results in the early
infection periods, or there is an analytical
problem at the laboratory (Joseph, 2020;
Susilo et al., 2020).
Because of these limitations, especially
in this pandemic, we need simple and
accurate testing to identify the SARS-CoV-2
infection quickly to prevent the virus from
spreading and produce the proper handling
for the suspected SARS-CoV-2 infection
patient (Joseph, 2020; Li et al., 2020).
In this case, the government has widely
distributed the rapid test kit to detect the
antibody of SARS-CoV-2. Rapid test
detection has many practical advantages,
including quick test results, low cost, and
patient convenience. This test can identify
the carrier patients and patients without
symptoms (Joseph, 2020; Li et al., 2020).
Moreover, many companies have
developed Rapid test kits to detect human
antibodies in SARS-CoV-2 patients (Guo et
al., 2020). A rapid test needs reconsidering
of the exposure onset and symptoms duration
before deciding the results. In this case, the
test can detect the IgM and IgA sooner. It is
detected three up to six days after the onset
of the symptoms. Meanwhile, it detects the
IgG within 10 to 18 days after the initial
symptoms (Guo et al., 2020).
In April 2020, the COVID-19 team for
West Java province, Indonesia, performed a
validation test for rapid test using ‘Wondfo’
compared with the RT-PCR. The sensitivity,
specificity, and accuracy rates in serum
specimens in that test were 62.9%, 95.2%,
and 77.1%, respectively. Meanwhile, in the
capillary, the rates were 44.4%, 100%, and
54.4% taken from 22 samples (Tim Tanggap
COVID-19, 2020). Li et al. (2020) stated
that the antibody-rapid test showed 88.66%
sensitivity and 90.63% specificity, measured
from 397 confirmed patients with RT-PCR
and 128 negative patients in eight health
facilities.
Since the rapid-test kits may have varied
sensitivity and specificity values, a validation
test for the rapid-test compared with the RT-
PCR is crucial, especially concerning the
situation of the outbreak in Indonesia. This
research took place at Bethesda Hospital
because it is one of the referral hospitals in
Yogyakarta.
The purpose of this study is to measure
the diagnostic performances, including
sensitivity, specificity, accuracy, positive
predictive value, negative predictive value,
and likelihood ratio of the antibody-rapid test
compared with the RT-PCR as the best
method for the SARS-CoV-2 suspected
patient in Bethesda Hospital, Yogyakarta.
METHODS
This study was analytical observational
research with a cross-sectional design
approach, and data sampling was collected
retrospectively. The research variables were
SARS-CoV-2 antibody rapid test as
independent variable and SARS-CoV-2 RT-
PCR as dependent variable.
Instruments in this study were electronic
medical record (ERM) and Laboratory
Information System (LIS) data from SARS-
CoV-2 suspected patients in Bethesda
Hospital, Yogyakarta. We collected
demographic data of patients with RT-PCR
of SARS-CoV-2 results from the Center for
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Environmental Engineering and Disease
Control (BBTKLPP) of Yogyakarta.
Meanwhile, we obtained the antibody-rapid
tests data using the Standard Q COVID-19
IgM/IgG Combo made in Korea. This study
has the approval number No.99/KEPK/-
RSB-VII/20 issued by the Medical and
Health Research Ethics Committee of
Bethesda Hospital Yogyakarta, Indonesia.
This study began from May to June 2020.
The inclusion criteria were SARS-CoV-2
suspected patient who was clinically
determined by attending physician, taking
nasopharyngeal/oropharyngeal swab RT-
PCR or antibody-rapid test, with no
immunocompromised problems.
The validation test for the SARS-CoV-2
antibody rapid test of Standard Q COVID-19
with immunochromatography compared with
SARS-CoV-2 RT-PCR was calculated using
a 2x2 table with a 95% level of confidence,
done with a diagnostic test calculator.
RESULTS AND DISCUSSION
Fifty subjects took the antibody-rapid
test and had data on the results of the RT-
PCR examination, consisting of 24 males and
26 females. From May until June 2020,
seven patients had confirmed SARS-CoV-2
infection based on the RT-PCR (Table 1).
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Ig M reactive 4 23 27
Ig M non reactive 3 20 23
Total 7 43 50
Ig G reactive 6 11 17
Ig G non reactive 1 32 33
Total 7 43 50






Ig M/Ig G reactive 7 11 18
Ig M/Ig G non reactive 0 32 32
Total 7 43 50
According to Table 2 and 3, there were
four reactive IgM and six reactive IgG from
seven positive confirmed RT-PCR. Three
patients had reactive IgM and IgG, and only
three patients had a reactive IgG, while only
one patient had a reactive IgM. Based on the
Standard Q COVID-19 IgM/IgG Combo
leaflet, individuals with reactive results for
IgM or IgG will show a reactive antibody
SARS-CoV-2 result.
From the seven positive confirmed
patients by RT-PCR, the antibody SARS-
CoV-2 could show reactive results between 7
to 14 days after the onset (two patients) and
more than 14 days after the initial symptom
(three patients). Also, two asymptomatic
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patients were confirmed positive by RT-PCR.
Meanwhile, Table 4, 5, and 6 show the
validation tests for the antibody rapid test
Standard Q COVID-19 IgM/IgG Combo
compared with RT-PCR. Based on the tables,
the validation test result for Standard Q
COVID-19 IgM/IgG Combo, the antibody
IgG was better than IgM.
Table 4. Validity of IgM to RT-PCR results







Table 5. Validity of IgG to RT-PCR results







Table 6. Validity of IgM/IgG to RT-PCR results






According to the manufacturer, the
specificity evaluation was done on 235 PCR-
negative samples and turned out to be
95.74% for both IgM and IgG. The
sensitivity of this test compared to the RT-
PCR from 66 specimens between 7 to 14
days after onset was 89.39% for IgM/IgG,
while from other 98 samples within 14 days
after onset was 96.94% for IgM/IgG (SD
biosensor, 2020). On the other hand, our
results showed that the specificity value from
43 patients with negative RT-PCR was
74.7%, while the sensitivity value from
seven patients with positive RT-PCR was
100%. Positive Predictive Value (PPV) was
38.9%, meaning that 61.6% reactive result
from this test showed a false-positive
compared with the RT-PCR result. Negative
Predictive Value (NPV) was 100%, meaning
that the non-reactive result from this test
showed that the patient did not get infected
by SARS-CoV-2 based on the RT-PCR.
Meanwhile, the likelihood ratio (LLR) value
was equal to 3,906, denoting that in every
one false positive, there were four correct
positive results. The greater the positive
likelihood ratio value is, the better it is to
detect disease (Putra et al., 2016).
In July 2020, the Indonesian Association
of Clinical Pathologists and Laboratory
Medicine (PDS PATKLIN) studied 63
different kinds of SARS-CoV-2 antibody
rapid tests from the communities and
hospitals in all the branches of PDS
PATKLIN in Indonesia. The result of the
study showed that the accuracy of SARS-
CoV-2 antibody rapid tests varied greatly.
The sensitivity and specificity of IgG ranged
around 33% to 96% and 19% to 100%.
Meanwhile, the sensitivity and specificity of
IgM ranged between 16% to 100% and 7%
to 97%, respectively.
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However, the result of our study showed
that the combination between the antibody
SARS-CoV-2 Standard Q COVID-19
Combo IgG and IgM had better accuracy if
compared to either IgG or IgM only, and the
performance of IgG was better than IgM.
Detection of IgM antibodies is often
interpreted as an indicator of acute infection,
while the detection of IgG antibodies
represents previous infection/immunity
(Castro et al., 2020). Yet, in this study, we
found three samples with positive RT-PCR
results that were only reactive IgG. It showed
that IgG could appear in the acute phase. Our
result was consistent with the PDS
PATKLIN survey. Long et al. (2020) found
that IgM seroconverted later than IgG. Thus,
they recommended that either IgM or IgG
seroconversion become a confirmation
criterion of recent SARS-CoV-2 infection.
So far, the RT-PCR method has some
limitations that involve the quality of
specimens, long turnaround times,
complicated operations, fluctuations of viral
load in different phases of SARS-CoV-2
infection, virus mutation probability, and
high prices. Therefore, the antibody-rapid
test is advisable, especially in screening the
specific population, individual traveling, and
contact tracing (Li et al., 2020; Long et al.,
2020; Kemenkes RI, 2020).
Based on Prevention Guidelines for
COVID-19, Fifth Revision Edition, the rapid
test was no longer recommended for
diagnosis. However, the study of Guo et al.
(2020) stated that the positive detection rate
increased by using combinations of antibody
rapid test and RT-PCR, especially if there
was a false negative from RT-PCR result
from the patient with highly suspected
SARS-CoV-2.
Meanwhile, our study has its limitations.
Firstly, the proportion of confirmed positive
cases for SARS-COV-2 was relatively small
(seven patients only) and from only one
health facility center (Bethesda Hospital).
CONCLUSION
The Standard Q COVID-19 IgM/IgG
Combo rapid test had a 100% sensitivity
value, 74.4% specificity value, 38.9%
positive predictive value, 100% negative
predictive value, and 3,906 positive
likelihood ratio.
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